Efficacy and safety of CT‐P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16‐week follow‐up study by Clive Grattan, Yevgeniya Dytyatkovska, Michał Springer, Maria Ratkova, Borislava Krusheva, Izabella Krupa‐Borek, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Yunju Bae, Suyoung Kim, Sewon Lee, Eunjin An, Jeong Eun Park, Jieun Ka, Jongho Kim, Sarbjit S. Saini

Get full text